Nemours

Logo GlobeNewswire
SciencePress Release2023-03-28 20:01:00
Company has initiated pre-IND discussions with the FDA for its first AIM INJ indication NEXI-001 completed enrollment in its final safety cohorts and all...

Logo PR Newswire
HealthPress Release2023-03-28 17:15:00
The new effort will rapidly accelerate the pace of cancer innovation, building on the White House Cancer Moonshot BOSTON, March 28, 2023 /PRNewswire/ --...

Logo Benzinga
Business / FinanceBy Business Wire2023-03-28 10:45:00
The long-term program is focused on significantly lowering the carbon footprint of Chemours' glycolic acid grades by up to 80% against a 2023 baseline The...

Logo GlobeNewswire
SciencePress Release2023-03-28 15:00:00
Martinsried /M unich, March 28, 202 3. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the...

Logo PR Newswire
HealthPress Release2023-03-29 07:08:00
STOCKHOLM, March 29, 2023 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin...

Logo PR Newswire
HealthPress Release2023-03-28 11:00:00
First-in-Class ERAP1 Inhibitor Enters Clinical Development Study to Evaluate GRWD5769 as Monotherapy, as well as in Combination with PD-1 Inhibitor Libtayo ®...

Logo PR Newswire
HealthPress Release2023-03-28 11:00:00
CAMBRIDGE, Mass., March 28, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused...

Logo GlobeNewswire
SciencePress Release2023-03-28 20:02:00
Figure 1: Swimmer Plot for Patients in the 200 mg Dose Cohort of the CPI-818 Phase 1/1b Clinical Trial for T Cell Lymphoma. The plot shows the tumor response...

Logo GlobeNewswire
SciencePress Release2023-03-28 11:30:00
Successful meeting with FDA to discuss registrational pathway for triple combination of PDS0101, PDS0301, and a commercial immune checkpoint inhibitor 100%...

Logo PR Newswire
HealthPress Release2023-03-28 12:00:00
OMAHA, Neb. and BELGRADE, Maine, March 28, 2023 /PRNewswire/ -- Bot Image, Inc., a Nebraska and Maine based Artificial Intelligence medical device company,...

Logo GlobeNewswire
SciencePress Release2023-03-28 13:39:00
SAN DIEGO, March 28, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients...

Logo GlobeNewswire
SciencePress Release2023-03-28 20:01:00
SAN DIEGO and TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company...

Logo GlobeNewswire
SciencePress Release2023-03-28 11:30:00
Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; potential for an additional $45...

Logo Benzinga
Business / FinanceBy Business Wire2023-03-29 07:01:00
Through AI/ML-enabled platform with a biology-first approach, Genialis looks to propel drug development, diagnostics and treatment planning Genialis, a...

Logo EIN Presswire
AutoPress Release2023-03-28 15:36:04
Our Mesothelioma Options Help Centers have a network of top doctors/surgeons from coast to coast. The Steinberg Law Group has decades of proven experience...

Logo The Independent
HealthBy Nina Massey2023-03-29 04:21:07
Scientists have found out how some skin cancers stop responding to treatment at the end of life. The findings allow researchers to see how melanoma evolves...

Logo PR Newswire
HealthPress Release2023-03-29 06:13:00
OSLO, Norway, March 29, 2023 /PRNewswire/ -- Navamedic ASA (OSE: NAVA), a Nordic pharma company and provider of high-quality products to hospitals and...

Logo GlobeNewswire
SciencePress Release2023-03-27 12:05:00
Experienced Leader Brings Extensive Clinical Development and Medical Affairs Expertise in Oncology FOSTER CITY, Calif., March 27, 2023 (GLOBE NEWSWIRE) --...

Logo GlobeNewswire
SciencePress Release2023-03-28 12:30:00
WORCESTER, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang or the Company) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company...

Logo GlobeNewswire
SciencePress Release2023-03-28 20:05:00
First cohort dosed in Phase 1 first-in-human dose-escalation study of VIP236, an v 3 small molecule drug conjugate (SMDC) in advanced solid tumors IND filing...